Method of prolonging cancerous patient survival in humans with hydrazine sulfate
US4867978A · kind A · utility
13Cited by
1References
7Claims
0Family size
Inventor
Key dates
| Filing date | Nov 25, 1988 |
| Grant date | Sep 19, 1989 |
| Priority date | — |
| Expiry date | Nov 25, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Hydrazine sulfate, alone or formulated with liquid or solid carriers, will prolong patient survival when administered to early-stage human cancer patients parenterally or orally.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.